$PBYI
PUMA BIOTECHNOLOGY, INC.

2019 Q3 Form 10-Q Financial Statement

#000156459019041793 Filed on November 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2018 Q4 2018 Q3
Revenue $56.35M $71.08M $62.63M
YoY Change -10.02% 228.95% 930.59%
Cost Of Revenue $9.370M $10.36M $9.048M
YoY Change 3.56% 155.8% 492.92%
Gross Profit $46.98M $60.72M $53.58M
YoY Change -12.32% 245.79% 1077.35%
Gross Profit Margin 83.37% 85.43% 85.55%
Selling, General & Admin $31.40M $40.93M $28.50M
YoY Change 10.17% 32.59% -12.27%
% of Gross Profit 66.84% 67.41% 53.19%
Research & Development $30.03M $38.33M $36.36M
YoY Change -17.42% -23.72% -26.55%
% of Gross Profit 63.91% 63.13% 67.86%
Depreciation & Amortization $200.0K $2.100M $2.060M
YoY Change -90.29% 54.41% 128.89%
% of Gross Profit 0.43% 3.46% 3.84%
Operating Expenses $70.80M $79.26M $73.91M
YoY Change -4.21% -2.29% -11.5%
Operating Profit -$14.45M -$18.54M -$11.28M
YoY Change 28.07% -70.83% -85.43%
Interest Expense $3.052M -$3.120M $3.499M
YoY Change -12.78% 524.0% 1028.71%
% of Operating Profit
Other Income/Expense, Net -$2.437M -$20.00K -$2.920M
YoY Change -16.54% 100.0% -1223.08%
Pretax Income -$16.89M -$30.68M -$14.20M
YoY Change 18.94% -52.12% -81.6%
Income Tax $20.00K
% Of Pretax Income
Net Earnings -$16.89M -$30.69M -$14.20M
YoY Change 18.9% -52.1% -81.6%
Net Earnings / Revenue -29.96% -43.18% -22.67%
Basic Earnings Per Share
Diluted Earnings Per Share -$434.3K -$803.7K -$373.3K
COMMON SHARES
Basic Shares Outstanding 38.89M 38.13M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2018 Q4 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $110.4M $165.4M $128.0M
YoY Change -13.75% 102.45% 20.41%
Cash & Equivalents $58.90M $108.4M $72.62M
Short-Term Investments $51.50M $57.00M $59.70M
Other Short-Term Assets $322.0K $1.787M $11.50M
YoY Change -97.2% -86.25% 23.6%
Inventory $3.123M $2.625M $2.832M
Prepaid Expenses $9.990M $12.40M
Receivables $27.18M $20.77M $19.75M
Other Receivables $2.500M $1.100M $11.20M
Total Short-Term Assets $151.1M $203.0M $174.4M
YoY Change -13.36% 90.8% 45.82%
LONG-TERM ASSETS
Property, Plant & Equipment $3.204M $3.963M $4.200M
YoY Change -23.71% -11.34% -10.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $16.10M $7.700M $6.700M
YoY Change 140.3% 22.22% -18.29%
Total Long-Term Assets $80.95M $56.12M $56.32M
YoY Change 43.72% -5.09% -9.59%
TOTAL ASSETS
Total Short-Term Assets $151.1M $203.0M $174.4M
Total Long-Term Assets $80.95M $56.12M $56.32M
Total Assets $232.0M $259.1M $230.7M
YoY Change 0.57% 56.55% 26.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.056M $20.68M $16.36M
YoY Change -44.66% -25.31% -7.03%
Accrued Expenses $76.77M $46.43M $41.52M
YoY Change 84.91% 51.5% -47.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $88.34M $67.12M $57.88M
YoY Change 52.63% 15.04% -40.51%
LONG-TERM LIABILITIES
Long-Term Debt $94.20M $151.9M $121.1M
YoY Change -22.21% 213.2%
Other Long-Term Liabilities $32.30M $5.800M $5.900M
YoY Change 447.46% 7.41% 9.26%
Total Long-Term Liabilities $126.5M $157.7M $127.0M
YoY Change -0.39% 192.58% 2251.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $88.34M $67.12M $57.88M
Total Long-Term Liabilities $126.5M $157.7M $127.0M
Total Liabilities $214.9M $224.8M $184.8M
YoY Change 16.26% 100.33% 79.95%
SHAREHOLDERS EQUITY
Retained Earnings -$1.266B -$1.202B -$1.171B
YoY Change 8.12% 10.43% 14.35%
Common Stock $1.284B $1.236B $1.217B
YoY Change 5.44% 8.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.18M $34.31M $45.91M
YoY Change
Total Liabilities & Shareholders Equity $232.0M $259.1M $230.7M
YoY Change 0.57% 56.55% 26.87%

Cashflow Statement

Concept 2019 Q3 2018 Q4 2018 Q3
OPERATING ACTIVITIES
Net Income -$16.89M -$30.69M -$14.20M
YoY Change 18.9% -52.1% -81.6%
Depreciation, Depletion And Amortization $200.0K $2.100M $2.060M
YoY Change -90.29% 54.41% 128.89%
Cash From Operating Activities -$7.310M $7.040M -$7.260M
YoY Change 0.69% -119.77% -86.78%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$60.00K -$300.0K
YoY Change -100.0% -99.88% 87.5%
Acquisitions
YoY Change
Other Investing Activities $38.98M $2.650M -$21.06M
YoY Change -285.09% -90.05% -147.61%
Cash From Investing Activities $38.98M $2.590M -$21.36M
YoY Change -282.49% -111.01% -148.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.00K 30.49M 1.010M
YoY Change -93.07% -50.11% -89.62%
NET CHANGE
Cash From Operating Activities -7.310M 7.040M -7.260M
Cash From Investing Activities 38.98M 2.590M -21.36M
Cash From Financing Activities 70.00K 30.49M 1.010M
Net Change In Cash 31.74M 40.12M -27.61M
YoY Change -214.96% 1926.26% 2387.39%
FREE CASH FLOW
Cash From Operating Activities -$7.310M $7.040M -$7.260M
Capital Expenditures $0.00 -$60.00K -$300.0K
Free Cash Flow -$7.310M $7.100M -$6.960M
YoY Change 5.03% -51.14% -87.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
108419000
dei Entity Address Address Line1
EntityAddressAddressLine1
10880 Wilshire Boulevard
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y6M
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P9Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y4M24D
pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
P8Y7M6D
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2150
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90024
CY2019Q3 us-gaap Deferred Rent Asset Net Current
DeferredRentAssetNetCurrent
39000
CY2019Q3 us-gaap Other Assets Current
OtherAssetsCurrent
322000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
151095000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20194000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3204000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3963000
CY2019Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
41447000
CY2018Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
44408000
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
13173000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4319000
CY2019Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
2931000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
3429000
dei Entity Address City Or Town
EntityAddressCityOrTown
Los Angeles
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
false
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1787000
CY2019Q3 us-gaap Inventory Net
InventoryNet
3123000
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
12397000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
203003000
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35703
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0683487
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2018Q4 us-gaap Inventory Net
InventoryNet
2625000
CY2019Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
51535000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
57002000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58904000
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
27182000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
20773000
CY2019Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9990000
dei Local Phone Number
LocalPhoneNumber
248-6500
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
us-gaap Operating Expenses
OperatingExpenses
239718000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11281000
us-gaap Operating Expenses
OperatingExpenses
256030000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14448000
us-gaap Net Income Loss
NetIncomeLoss
-82880000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-16885000
pbyi Cost Of Sales
CostOfSales
24262000
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31402000
pbyi Cost Of Sales
CostOfSales
26673000
CY2018Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
28502000
CY2018Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1010000
CY2018Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-14201000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
7151000
dei City Area Code
CityAreaCode
424
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
110435000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
105239000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30027000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36360000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
102610000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3000000.0
CY2019Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
900000
CY2019Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3900000
CY2019Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3900000
CY2019Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
3900000
CY2019Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
3900000
CY2019Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Six
FiniteLivedIntangibleAssetsAmortizationExpenseYearSix
3900000
CY2019Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Seven
FiniteLivedIntangibleAssetsAmortizationExpenseYearSeven
3900000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
104532000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5595000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-60205000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
7151000
us-gaap Net Income Loss
NetIncomeLoss
-64396000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
20684000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
76771000
CY2019Q3 us-gaap Assets
Assets
232044000
CY2018Q4 us-gaap Assets
Assets
259122000
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9056000
CY2018Q4 us-gaap Long Term Debt
LongTermDebt
151886000
CY2019Q3 us-gaap Liabilities
Liabilities
214864000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
46431000
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2516000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
88343000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
67115000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
5815000
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23336000
CY2019Q3 pbyi Post Marketing Commitment Liability Noncurrent
PostMarketingCommitmentLiabilityNoncurrent
9000000
CY2019Q3 us-gaap Long Term Debt
LongTermDebt
94185000
CY2018Q4 us-gaap Liabilities
Liabilities
224816000
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38943774
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38943774
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38325037
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38325037
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1283498000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1236355000
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
115000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1266437000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1202041000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
17180000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
34306000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
232044000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
259122000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
56352000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62629000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
209338000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
179912000
CY2019Q3 pbyi Cost Of Sales
CostOfSales
9371000
CY2018Q3 pbyi Cost Of Sales
CostOfSales
9048000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
126529000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
70800000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
73910000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30380000
us-gaap Operating Income Loss
OperatingIncomeLoss
-76118000
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
569000
CY2018Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
590000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2349000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1093000
CY2019Q3 us-gaap Interest Expense
InterestExpense
3052000
CY2018Q3 us-gaap Interest Expense
InterestExpense
3499000
us-gaap Interest Expense
InterestExpense
11943000
us-gaap Interest Expense
InterestExpense
7165000
pbyi Legal Verdict Expenses
LegalVerdictExpenses
16350000
us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
-8103000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
46000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
31000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-690000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2437000
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2920000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-34016000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6762000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-16885000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-14201000
us-gaap Net Income Loss
NetIncomeLoss
-64396000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16885000
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14201000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-64396000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-82880000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.67
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.19
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38893757
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38043174
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38675961
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37855249
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-14201000
us-gaap Net Income Loss
NetIncomeLoss
-82880000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
15000
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
115000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2019Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
10000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-12000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16880000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14203000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64269000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-82883000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
21771000
CY2019Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
76000
CY2019Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
5000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
17180000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
38299000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20807000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
45913000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
34306000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
45791000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1352000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
127000
us-gaap Net Income Loss
NetIncomeLoss
-64396000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
17180000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
53302000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
68343000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-3000
us-gaap Net Income Loss
NetIncomeLoss
-82880000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
45913000
us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
-289000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6409000
us-gaap Share Based Compensation
ShareBasedCompensation
45791000
us-gaap Share Based Compensation
ShareBasedCompensation
68343000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-54000
us-gaap Profit Loss
ProfitLoss
-64396000
us-gaap Profit Loss
ProfitLoss
-82880000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6178000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5279000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-8047000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10080000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
498000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
803000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-2905000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-244000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1465000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
11495000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-11628000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-11388000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
30340000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
10869000
us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
39000
us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
-470000
pbyi Increase Decrease In Post Marketing Commitment Liability
IncreaseDecreaseInPostMarketingCommitmentLiability
9000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
20810000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31152000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
550000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
127072000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
71112000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
28135000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
11457000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1352000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
25000000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
75000000
us-gaap Repayments Of Debt
RepaymentsOfDebt
80000000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
7793000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
5625000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
4192000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-67066000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
77959000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-40661000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13398000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
112738000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
86015000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
72077000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
72617000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
59000
us-gaap Interest Paid Net
InterestPaidNet
9464000
us-gaap Interest Paid Net
InterestPaidNet
5134000
pbyi Number Of Subsidiaries
NumberOfSubsidiaries
2
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-16900000
us-gaap Net Income Loss
NetIncomeLoss
-64400000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
20800000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58900000
CY2019Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
51500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates: </p> <p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with Generally Accepted Accounting Principles, or GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of expenses for the period presented. Accordingly, actual results could differ from those estimates. </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant estimates include estimates for variable consideration for which reserves were established.  These estimates are included in the calculation of net revenues and include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company’s sale of its products. </p>
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1000000.0
CY2019Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Eight
FiniteLivedIntangibleAssetsAmortizationExpenseYearEight
3900000
CY2019Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Nine
FiniteLivedIntangibleAssetsAmortizationExpenseYearNine
3900000
CY2019Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Ten
FiniteLivedIntangibleAssetsAmortizationExpenseYearTen
3900000
CY2019Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Eleven
FiniteLivedIntangibleAssetsAmortizationExpenseYearEleven
3900000
CY2019Q3 pbyi Finite Lived Intangible Assets Amortization Expense Year Twelve
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwelve
1000000.0
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.
us-gaap Lessee Operating Lease Option To Terminate
LesseeOperatingLeaseOptionToTerminate
Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.
CY2019Q1 pbyi Average Incremental Borrowing Rate
AverageIncrementalBorrowingRate
0.109
pbyi Research And Development Expense Related To Inventory
ResearchAndDevelopmentExpenseRelatedToInventory
4500000
CY2019Q3 pbyi Incremental Costs Expenses
IncrementalCostsExpenses
0
CY2019Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
92355000
CY2019Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
115000
CY2019Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
92470000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
143330000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
12000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
143318000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk: </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents and accounts receivable. The Company’s cash and cash equivalents and restricted cash in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at September 30, 2019, were approximately $75.7 million. The Company does not believe it is exposed to any significant credit risk due to the nature of the financial instruments in which the money is held. Pursuant to the Company’s internal investment policy, investments must be rated A-1/P-1 or better by Standard and Poor’s Rating Service and Moody’s Investors Service at the time of purchase. </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sells its products in the United States primarily through specialty pharmacies and specialty distributors. Therefore, wholesale distributors and large pharmacy chains account for a large portion of its trade receivables and net product revenue. The Company monitors the creditworthiness of its customers and has internal policies regarding customer credit limits. The Company estimates an allowance for doubtful accounts primarily based on the credit worthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s success depends on its ability to successfully commercialize NERLYNX.  The Company currently has a single product with limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, NERLYNX, and expects NERLYNX to constitute the vast majority of product revenue for the foreseeable future. The Company’s success depends on its ability to effectively commercialize NERLYNX. </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company relies exclusively on third parties to formulate and manufacture NERLYNX and its drug candidates. The commercialization of NERLYNX and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those third parties fail to provide sufficient quantities of product or fail to do so at acceptable quality or price. The Company has no experience in drug formulation or manufacturing and does not intend to establish its own manufacturing facilities. The Company lacks the resources and expertise to formulate or manufacture NERLYNX or its drug candidates. While the drug candidates were being developed by Pfizer, both the drug substance and drug product were manufactured by third-party contractors. The Company is using the same third-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and the commercialization of NERLYNX. If the Company is unable to continue its relationships with one or more of these third-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. </span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p>
CY2019Q3 pbyi Cash And Cash Equivalents And Restricted Cash In Excess Of Insured Limits
CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits
75700000
pbyi Reserve On Research And Development Tax Credit Percent
ReserveOnResearchAndDevelopmentTaxCreditPercent
0.20
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q3 us-gaap Accounts Receivable Gross
AccountsReceivableGross
24682000
CY2018Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
20773000
CY2019Q3 pbyi License Revenue Receivable
LicenseRevenueReceivable
2500000
CY2019Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
27182000
CY2018Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
20773000
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9990000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12397000
CY2019Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
2931000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
3429000
CY2019Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
12921000
CY2018Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
15826000
CY2019Q3 us-gaap Other Assets Current
OtherAssetsCurrent
322000
CY2018Q4 us-gaap Insurance Settlements Receivable Current
InsuranceSettlementsReceivableCurrent
1175000
CY2019Q3 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
322000
CY2018Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
612000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1787000
pbyi Fixed Lease Expense
FixedLeaseExpense
3600000
us-gaap Variable Lease Cost
VariableLeaseCost
300000
us-gaap Sublease Income
SubleaseIncome
100000
CY2019Q3 us-gaap Sublease Income
SubleaseIncome
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
4050000
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.109
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1274000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5207000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5365000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5483000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5631000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
13296000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
36256000
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10404000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
25852000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
4924000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
5141000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
5300000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
5464000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
5631000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
13296000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
39756000
CY2019Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8833000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9139000
CY2019Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5629000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5176000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3204000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3963000
CY2019Q3 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
700000
CY2019Q3 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
50000000
CY2019Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8553000
CY2019Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
41447000
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1000000.0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3000000.0
CY2019Q3 pbyi Accrued Legal Verdict Expense Current
AccruedLegalVerdictExpenseCurrent
31350000
CY2018Q4 pbyi Accrued Legal Verdict Expense Current
AccruedLegalVerdictExpenseCurrent
9000000
CY2019Q3 pbyi Accrued Development Costs
AccruedDevelopmentCosts
13923000
CY2018Q4 pbyi Accrued Development Costs
AccruedDevelopmentCosts
10187000
CY2019Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
8040000
CY2018Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
9162000
CY2019Q3 pbyi Accrued Variable Consideration Current
AccruedVariableConsiderationCurrent
6406000
CY2018Q4 pbyi Accrued Variable Consideration Current
AccruedVariableConsiderationCurrent
3818000
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3569000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4435000
CY2019Q3 pbyi Accrued Professional Fees Liability Current
AccruedProfessionalFeesLiabilityCurrent
1061000
CY2018Q4 pbyi Accrued Professional Fees Liability Current
AccruedProfessionalFeesLiabilityCurrent
2175000
CY2019Q3 pbyi Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
3425000
CY2018Q4 pbyi Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
2380000
CY2019Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
5119000
CY2018Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1705000
CY2019Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
886000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1379000
CY2019Q3 pbyi Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
1095000
CY2018Q4 pbyi Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
788000
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1897000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1402000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
76771000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
46431000
CY2019Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
100000000
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2024-06-01
CY2019Q3 pbyi Accretion Of Final Interest Payment
AccretionOfFinalInterestPayment
1603000
CY2019Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
7418000
CY2019Q3 us-gaap Long Term Debt
LongTermDebt
94185000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
531112
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
332173
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q3 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2021-10-04
CY2019Q3 pbyi Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
12213000
CY2018Q3 pbyi Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
20807000
pbyi Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
45791000
pbyi Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
68343000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5708544
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
87.49
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7762000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
129734
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
27.76
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
69969
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
40.50
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
87625
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
15.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
995000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
603918
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
102.39
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5076766
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
86.08
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2450000
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
396948
CY2019Q3 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice
39.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
21.82
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
56.46
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
779292
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
33.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
129734
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
21.82
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
442109
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
35.13
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
69969
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
25.06
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
396948
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
29.85
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1200000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1300000
CY2019Q3 pbyi Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
187500000

Files In Submission

Name View Source Status
0001564590-19-041793-index-headers.html Edgar Link pending
0001564590-19-041793-index.html Edgar Link pending
0001564590-19-041793.txt Edgar Link pending
0001564590-19-041793-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pbyi-10q_20190930.htm Edgar Link pending
pbyi-10q_20190930_htm.xml Edgar Link completed
pbyi-20190930.xsd Edgar Link pending
pbyi-20190930_cal.xml Edgar Link unprocessable
pbyi-20190930_def.xml Edgar Link unprocessable
pbyi-20190930_lab.xml Edgar Link unprocessable
pbyi-20190930_pre.xml Edgar Link unprocessable
pbyi-ex101_131.htm Edgar Link pending
pbyi-ex311_7.htm Edgar Link pending
pbyi-ex312_9.htm Edgar Link pending
pbyi-ex321_6.htm Edgar Link pending
pbyi-ex322_10.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending